Epichem

Executive Summary

Epichem is an Australian contract research organization (CRO) providing specialized medicinal, synthetic, and analytical chemistry services to support drug discovery and development. Founded in 2020 and headquartered in Perth, the company serves clients across oncology, infectious diseases, and neurology. Its offerings include custom synthesis, reference standards, impurity profiling, and analytical services. As a platform-stage private company with 50–200 employees, Epichem benefits from the growing trend of pharmaceutical and biotech outsourcing. The company's business model generates recurring revenue through service contracts, reducing the inherent risk of drug development. However, competition in the CRO space and reliance on client spending are key considerations. Epichem is well-positioned to capture demand from Australian and global drug developers seeking high-quality chemistry support.

Upcoming Catalysts (preview)

• Q3 2026Major Contract Win with Large Pharma70% success
• Q2 2027Facility Expansion to Increase Capacity80% success
• Q1 2027Strategic Partnership with Biotech Accelerator65% success